RGX-314 Gene Therapy Administered in the Suprachoroidal Space for Participants With Neovascular Age-Related Macular Degeneration (nAMD)

Inclusion Criteria:

• Age >/= 50 and </= 89

• Diagnosis of CNV secondary to age-related macular degeneration in the study eye.

• Participants must have demonstrated a meaningful response to anti-VEGF therapy.

• Willing and able to provide written, signed informed consent for this study.

Exclusion Criteria:

• CNV or macular edema in the study eye secondary to any causes other than AMD.

• Subfoveal fibrosis or atrophy in study eye.

• Participants who have had a prior vitrectomy.

• Active or history of retinal detachment in the study eye.

• History of intravitreal therapy in the study eye, such as intravitreal steroidinjection or investigational product (IP), other than anti-VEGF therapy, in the 6months prior to study entry.

• Received any gene therapy.

• Any condition preventing visualization of the fundus or VA improvement in the studyeye, eg, cataract.

• History of intraocular surgery in the study eye within 12 weeks of study entry.

• Receipt of any IP within 30 days of study entry or 5 half-lives of the IP.

• Myocardial infarction, cerebrovascular accident, or transient ischemic attackswithin 6 months of study entry.

• Cohorts 1 - 5 only: Uncontrolled glaucoma in the study eye.

COHORT 6 AND 7 ONLY:

• Active or history of glaucoma or ocular hypertension (steroid-induced ocularhypertension (Cohort 7 only)) in the study eye.

• Certain OCT characteristics including: Large Pigment Epithelial Detachments (PED),clinically significant Epiretinal Membrane (ERM) in the study eye at Visit 1.

Note: Other inclusion/exclusion criteria apply.